Cargando…

Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement

BACKGROUND: As vitamins and dietary supplements are obtainable without prescription, treating physicians often ignore their intake by patients with multiple sclerosis (MS) and may therefore miss potential adverse effects and interactions. OBJECTIVE: We aimed to assess the spectrum and intake frequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Pape, Katrin, Steffen, Falk, Zipp, Frauke, Bittner, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457677/
https://www.ncbi.nlm.nih.gov/pubmed/32922829
http://dx.doi.org/10.1177/2055217320936318
_version_ 1783576043761696768
author Pape, Katrin
Steffen, Falk
Zipp, Frauke
Bittner, Stefan
author_facet Pape, Katrin
Steffen, Falk
Zipp, Frauke
Bittner, Stefan
author_sort Pape, Katrin
collection PubMed
description BACKGROUND: As vitamins and dietary supplements are obtainable without prescription, treating physicians often ignore their intake by patients with multiple sclerosis (MS) and may therefore miss potential adverse effects and interactions. OBJECTIVE: We aimed to assess the spectrum and intake frequency of supplementary medication in a cohort of MS patients and to analyse the effect of biotin intake on measurement of serum neurofilament light chain (sNfL), an emerging marker of disease activity. METHODS: MS patients visiting our neurology outpatient clinic completed a questionnaire on their past or present use of vitamins or dietary supplements. In addition, the impact of two different doses of biotin (10 and 300 mg/day) on sNfL was studied in healthy volunteers. RESULTS: Of 186 patients, 72.6% reported taking over-the-counter vitamins or dietary supplements currently or previously. Most frequently used was vitamin D (60.0%), followed by biotin. Female patients and patients with primary progressive MS tended to use supplements more frequently. Biotin intake did not interfere with sNfL measurement by single molecule array (Simoa). CONCLUSIONS: The use of vitamins and dietary supplements is frequent among patients with MS. Thus, treating physicians should be aware of the pitfalls of supplementary treatment and educate their patients accordingly.
format Online
Article
Text
id pubmed-7457677
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74576772020-09-11 Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement Pape, Katrin Steffen, Falk Zipp, Frauke Bittner, Stefan Mult Scler J Exp Transl Clin Original Research Paper BACKGROUND: As vitamins and dietary supplements are obtainable without prescription, treating physicians often ignore their intake by patients with multiple sclerosis (MS) and may therefore miss potential adverse effects and interactions. OBJECTIVE: We aimed to assess the spectrum and intake frequency of supplementary medication in a cohort of MS patients and to analyse the effect of biotin intake on measurement of serum neurofilament light chain (sNfL), an emerging marker of disease activity. METHODS: MS patients visiting our neurology outpatient clinic completed a questionnaire on their past or present use of vitamins or dietary supplements. In addition, the impact of two different doses of biotin (10 and 300 mg/day) on sNfL was studied in healthy volunteers. RESULTS: Of 186 patients, 72.6% reported taking over-the-counter vitamins or dietary supplements currently or previously. Most frequently used was vitamin D (60.0%), followed by biotin. Female patients and patients with primary progressive MS tended to use supplements more frequently. Biotin intake did not interfere with sNfL measurement by single molecule array (Simoa). CONCLUSIONS: The use of vitamins and dietary supplements is frequent among patients with MS. Thus, treating physicians should be aware of the pitfalls of supplementary treatment and educate their patients accordingly. SAGE Publications 2020-08-27 /pmc/articles/PMC7457677/ /pubmed/32922829 http://dx.doi.org/10.1177/2055217320936318 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Paper
Pape, Katrin
Steffen, Falk
Zipp, Frauke
Bittner, Stefan
Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement
title Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement
title_full Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement
title_fullStr Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement
title_full_unstemmed Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement
title_short Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement
title_sort supplementary medication in multiple sclerosis: real-world experience and potential interference with neurofilament light chain measurement
topic Original Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457677/
https://www.ncbi.nlm.nih.gov/pubmed/32922829
http://dx.doi.org/10.1177/2055217320936318
work_keys_str_mv AT papekatrin supplementarymedicationinmultiplesclerosisrealworldexperienceandpotentialinterferencewithneurofilamentlightchainmeasurement
AT steffenfalk supplementarymedicationinmultiplesclerosisrealworldexperienceandpotentialinterferencewithneurofilamentlightchainmeasurement
AT zippfrauke supplementarymedicationinmultiplesclerosisrealworldexperienceandpotentialinterferencewithneurofilamentlightchainmeasurement
AT bittnerstefan supplementarymedicationinmultiplesclerosisrealworldexperienceandpotentialinterferencewithneurofilamentlightchainmeasurement